Back to mobile site

Incyte (INCY) Phase 3 ECHO-301 Study Didn't Meet Primary Endpoint

April 6, 2018 7:32 AM EDT Send to a Friend
Incyte Corporation (Nasdaq: INCY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login